KLRS Key Statistics, Chart & Performance
The current stock price of KLRS is 9.78 USD. In the past month the price increased by 29.19%.
KLRS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About KLRS
Company Profile
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. The company is headquartered in Berkeley Heights, New Jersey and currently employs 6 full-time employees. The company went IPO on 2020-07-30. The firm is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Company Info
KALARIS THERAPEUTICS INC
400 Connell Drive, Suite 5500
Berkeley Heights NEW JERSEY US
Employees: 6
Phone: 16502492727
KALARIS THERAPEUTICS INC / KLRS FAQ
What does KALARIS THERAPEUTICS INC do?
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. The company is headquartered in Berkeley Heights, New Jersey and currently employs 6 full-time employees. The company went IPO on 2020-07-30. The firm is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
What is the stock price of KALARIS THERAPEUTICS INC today?
The current stock price of KLRS is 9.78 USD. The price increased by 18.4% in the last trading session.
Does KLRS stock pay dividends?
KLRS does not pay a dividend.
How is the ChartMill rating for KALARIS THERAPEUTICS INC?
KLRS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in KALARIS THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on KLRS.
What is the next earnings date for KLRS stock?
KALARIS THERAPEUTICS INC (KLRS) will report earnings on 2026-03-05, after the market close.
KLRS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to KLRS.
KLRS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KLRS. No worries on liquidiy or solvency for KLRS as it has an excellent financial health rating, but there are worries on the profitability.
KLRS Financial Highlights
Over the last trailing twelve months KLRS reported a non-GAAP Earnings per Share(EPS) of -7.39. The EPS decreased by -36.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.7% | ||
| ROE | -123.51% | ||
| Debt/Equity | 0 |
KLRS Forecast & Estimates
12 analysts have analysed KLRS and the average price target is 18.87 USD. This implies a price increase of 92.94% is expected in the next year compared to the current price of 9.78.